Association of itraconazole and fuming nitric acid in the treatment of chromycosis: a new therapeutic option
Abstract
INTRODUCTION: Chromoblastomycosisis a chronic fungal infection of the skin and subcutaneous tissue, associated with low cure rates and high recurrence rates. AIM: To describe the association of itraconazole and fuming nitric acid in the treatment of chromoblastomycosis,being the first report in the literature. REPORT: a male patient presented, two years ago, with verrucous plaque affecting the left malleolar region. Clinical and histopathological findings confirmed the diagnosis of chromoblastomycosis. Initial treatment was performed with itraconazole, with no response to therapy. Afterwards, chemical cauterization was associated with itraconazole through the topical application of Fuming Nitric Acid (NFA) with significant improvement of the lesions. DISCUSSION: ANF triggers an oxidation process that results in cell necrosis. The proposed therapy is low-cost, with a good response in a short period of time, in addition to improving the quality of life and socioeconomic indices of this population.
References
2. Brito AC, Bittencourt MJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic and treatment up-date. An Bras Dermatol. 2018;93(4):495-506.
3. Castro LGM, Salebian A, Lacaz CS. Fungal cells remain viable for up to 12 days in chromomycosis lesions treated by cryosurgery with liquid nitrogen. An Bras Dermatol. 2003;78(3):279-282.
4. FISPQ. Ficha de Informações de Segurança de Produto Químico. Ácido Nítrico Concentrado, 2017 [acesso 22 maio 2019]. Disponível em: http://gotaquimica.com.br/wp-content/uploads/2017/08/%C3%81cido-N%C3%ADtrico-69.pdf
5. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Medical Mycology. 2009;47(1):3-15.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: 
author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
Copyright ownership
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License © Copyright Policy
Any permissions should be requested to PLSclear.com
